Saba Capital Management, L.P., a significant investor owning around ten percent of BlackRock ESG Capital Allocation Term Trust (NASDAQ: ECAT), has recently reported a reduction in its stake through the sale of 272,613 common shares in two tranches. These sales took place on January 20 and January 21, 2026, with share prices ranging narrowly between $15.38 and $15.39, culminating in roughly $4,193,816 in total proceeds.
On January 20, 2026, Saba Capital disposed of 102,837 shares at a unit price of $15.39. This transaction brought their remaining holdings down to 25,968,064 shares. The subsequent day, January 21, 2026, saw another sale of 169,776 shares at a price slightly lower at $15.38 per share, further trimming their position to 25,798,288 shares. Despite this divestment, ECAT remains an attractive income vehicle, currently trading at around $15.50 per share and offering an impressive dividend yield of 21.57%. The trust enjoys a market capitalization close to $1.53 billion.
Performance data from InvestingPro underscores ECAT’s solid returns, with a 13.96% total return recorded over the past year. Moreover, the trust is recognized for its generally low price volatility, factors that contribute to its financial health rating categorized as "GREAT." These attributes underscore ECAT’s role as a significant dividend payer within the market.
The insider sales were formally disclosed in a Securities and Exchange Commission Form 4 filing, signed by Zachary Gindes on behalf of Saba Capital Management, L.P., and Boaz Weinstein, on January 22, 2026. This filing details the timing and scale of the share sales, reflecting a strategic portfolio adjustment by Saba Capital.
Such movements by a ten-percent stakeholder in a notable ESG-focused investment vehicle bear importance for stakeholders monitoring shareholder confidence and institutional investment trends within environmentally focused financial products. While the sales represent a measurable reduction in shares held, the continued substantial ownership indicates sustained interest in ECAT's long-term outlook.